NCT05798390Visszavonva
Treatment With Bempedoic Acid And/Or Its Fixed-dose Combination With Ezetimibe in Routine Clinical Practice in Patients With Primary Hypercholesterolemia Or Mixed Dyslipidemia
Non-Interventional Study On The Treatment With Bempedoic Acid And/Or Its Fixed-dose Combination With Ezetimibe in Routine Clinical Practice in Patients With Primary Hypercholesterolemia Or Mixed Dyslipidemia
Forrás: ClinicalTrials.gov · Utoljára frissítve: 2023. dec. 6.
Megadott ok: Due to patient availability
Rövid összefoglaló (regiszter, angolul)
Cardiovascular disease (CVD), especially its management and associated costs, remains a major concern globally. There is a direct correlation between circulating levels of low-density lipoprotein cholesterol (LDL-C) and the incidence of CVD. This study will assess bempedoic acid/FDC in a real-world clinical setting in adult patients in Spain with hypercholesterolaemia or mixed dyslipidemia.
- Állapot (regiszter)
- Visszavonva
- Vizsgálattípus
- Megfigyeléses
- Résztvevők száma
- 0 (tényleges)
- Első benyújtás
- 2023. márc. 10.
- Kezdés
- 2023. szept. 1.
- Elsődleges befejezés
- 2026. ápr. 1.
- Fő szponzor
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
- Betegségek
- Familiáris hiperkoleszterinémia
- NCT-szám
- NCT05798390
Ki nem vehet részt
Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.
Egyéb
- As this is a non-interventional study, no explicit exclusion criteria exist in order to avoid selection bias and to allow for documentation of routine clinical practice.
Kiket keres a vizsgálat
- Written informed consent to participate
- At least 18 years of age
- Participants suffering from documented primary hypercholesterolemia or mixed dyslipidemia
- Part 1: For participants treated to a maximum of 6 months or intended to be treated with bempedoic acid/FDC under usual clinical practice conditions and as long as the decision of the physician to start treatment is prior to the inclusion of the participant in the study at the discretion of the physician under no reimbursement conditions at enrollment
- Part 2: For participants treated or intended to be treated with bempedoic acid/FDC under usual clinical practice conditions and as long as the decision of the physician to start treatment is prior to the inclusion of the patient in the study under reimbursed conditions at enrollment
- No contraindications exist according to the SmPC of bempedoic acid/ FDC
- No concurrent participation in an interventional study (Simultaneous participation in other non-interventional studies is possible)
- Life expectancy > 1 -year
Életkor a regiszterben: 18 év – - · Nem: nők és férfiak · Egészséges önkénteseket nem fogad
Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.